v3.26.3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Mar. 31, 2025 [1] $ (25) $ 299,990 $ (286,322) $ (60) $ 758 $ 14,341
Balance, shares at Mar. 31, 2025 [1] 206,427            
Issuance of common stock Reverse Stock Split rounding [1]
Issuance of common stock Reverse Stock Split rounding, shares [1] 3            
Stock-based compensation [1] 1,467 110 1,577
Other comprehensive (income) loss [1] 127 127
Net loss [1] (7,691) (387) (8,078)
Issuance of common stock – At the Market equity offering [1] 2,441 2,441
Issuance of common stock - At the Market equity offering, shares [1] 28,235            
Balance at Jun. 30, 2025 [1] (25) 303,898 (294,013) 67 481 10,408
Balance, shares at Jun. 30, 2025 [1] 234,665            
Balance at Mar. 31, 2025 [1] (25) 299,990 (286,322) (60) 758 14,341
Balance, shares at Mar. 31, 2025 [1] 206,427            
Net loss             (16,336)
Balance at Sep. 30, 2025 [1] (25) 314,626 (301,953) 85 362 13,095
Balance, shares at Sep. 30, 2025 [1] 400,476            
Balance at Jun. 30, 2025 [1] (25) 303,898 (294,013) 67 481 10,408
Balance, shares at Jun. 30, 2025 [1] 234,665            
Issuance of common stock for warrant exercise [1] 2,868 2,868
Issuance of common stock for warrant exercise, shares [1] 71,957            
NeuroNOS issuance of stock [1] 414 86 500
Stock-based compensation [1] 1,662 113 1,775
Other comprehensive (income) loss [1] 18 18
Net loss [1] (7,940) (318) (8,258)
Issuance of common stock – At the Market equity offering [1] 5,694 5,694
Issuance of common stock - At the Market equity offering, shares [1] 93,854            
Issuance of warrants through September 2025 Inducement [1] 90 90
Balance at Sep. 30, 2025 [1] (25) 314,626 (301,953) 85 362 13,095
Balance, shares at Sep. 30, 2025 [1] 400,476            
Balance at Mar. 31, 2026 [2] (25) 325,588 (319,571) 134 84 6,210
Balance, shares at Mar. 31, 2026 [2] 589,639            
Issuance of common stock for warrant exercise [2]
Issuance of common stock for warrant exercise, shares [2] 95,000            
Issuance of common stock Reverse Stock Split rounding [2]
Issuance of common stock Reverse Stock Split rounding, shares [2] 87            
Issuance of common stock for conversion of debt [2] 540 540
Issuance of common stock for conversion of debt, shares [2] 58,692            
NeuroNOS issuance of stock [2] 2,361 867 3,228
Stock-based compensation [2] 926 110 1,036
Other comprehensive (income) loss [2] (21) (21)
Net loss [2] (7,935) (219) (8,154)
Balance at Jun. 30, 2026 [2] (25) 329,415 (327,506) 113 842 2,839
Balance, shares at Jun. 30, 2026 [2] 743,418            
Balance at Mar. 31, 2026 [2] (25) 325,588 (319,571) 134 84 6,210
Balance, shares at Mar. 31, 2026 [2] 589,639            
Net loss             (16,329)
Balance at Sep. 30, 2026 [2] (25) 340,604 (335,324) 72 797 6,124
Balance, shares at Sep. 30, 2026 [2] 1,620,615            
Balance at Jun. 30, 2026 [2] (25) 329,415 (327,506) 113 842 2,839
Balance, shares at Jun. 30, 2026 [2] 743,418            
Issuance of common stock for warrant exercise [2]
Issuance of common stock for warrant exercise, shares [2] 448,574            
Issuance of common stock for conversion of debt [2] 1,213 1,213
Issuance of common stock for conversion of debt, shares [2] 261,612            
NeuroNOS issuance of stock [2] 457 296 753
Stock-based compensation [2] 410 16 426
Other comprehensive (income) loss [2] (41) (41)
Net loss [2] (7,818) (357) (8,175)
Sale of common stock and pre-funded warrants [2] 9,109 9,109
Sale of common stock and pre-funded warrants, shares [2] 167,011            
Balance at Sep. 30, 2026 [2] $ (25) $ 340,604 $ (335,324) $ 72 $ 797 $ 6,124
Balance, shares at Sep. 30, 2026 [2] 1,620,615            
[1] Prior period results have been adjusted to reflect the one-for-twenty reverse stock split in July 2026. See Note 1, Organization and Business for details.
[2] Prior period results have been adjusted to reflect the one-for-twenty reverse stock split in July 2026. See Note 1, Organization and Business for details.